Array BioPharma IncFind Ratings Reports
ARRAY BIOPHARMA INC's gross profit margin for the fourth quarter of its fiscal year 2016 has significantly increased when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. ARRAY BIOPHARMA INC is extremely liquid. Currently, the Quick Ratio is 2.85 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year.
At the same time, stockholders' equity ("net worth") has significantly decreased by 188.93% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q4 FY16||Q4 FY15|
|Net Sales ($mil)||43.21||12.32|
|Net Income ($mil)||-25.01||-12.73|
|Balance Sheet||Q4 FY16||Q4 FY15|
|Cash & Equiv. ($mil)||109.94||178.33|
|Total Assets ($mil)||168.9||198.21|
|Total Debt ($mil)||113.66||107.28|
|Profitability||Q4 FY16||Q4 FY15|
|Gross Profit Margin||87.98||50.88|
|Return on Assets||-54.96||4.72|
|Return on Equity||0.0||21.96|
|Debt||Q4 FY16||Q4 FY15|
|Share Data||Q4 FY16||Q4 FY15|
|Shares outstanding (mil)||143.69||142.11|
|Div / share||0.0||0.0|
|Book value / share||-0.26||0.3|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||1944093.0||1927706.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. Along with this, the price-to-book ratio is also meaningless due to a negative book value for the company, making any comparisons useless. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average.
|ARRY NM||Peers 42.78||ARRY NM||Peers 21.27|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
ARRY's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
ARRY's P/CF is negative making the measure meaningless.
|ARRY NM||Peers 31.52||ARRY NA||Peers 0.49|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
ARRY's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|ARRY NM||Peers 10.46||ARRY -6600.00||Peers 1.93|
Neutral. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
ARRY's P/B is negative making this valuation measure meaningless.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, ARRY is expected to significantly trail its peers on the basis of its earnings growth rate.
|ARRY 3.66||Peers 690.55||ARRY 4.51||Peers 51.56|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
ARRY is trading at a significant discount to its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
ARRY significantly trails its peers on the basis of sales growth